Dopaminergic system genes in childhood aggression: Possible role for DRD2

World Journal of Biological Psychiatry

Volumn 13, Issue 1, 2012, Pages 65-74

  Zai, Clement C ^a,b   Ehtesham, Sahar ^a   Choi, Esther ^a   Nowrouzi, Behdin ^a   De Luca, Vincenzo ^a   Stankovich, Larisa ^a   Davidge, Kristen ^b   Freeman, Natalie ^a   King, Nicole ^a   Kennedy, James L ^a,b   Beitchman, Joseph H ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aggression; Childhood; Dopamine receptor (DRD2, DRD4); Dopamine transporter (DAT1, SLC6A3); Genetics

Indexed keywords

ALANINE; CYSTEINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; GLYCINE; THREONINE;

ADOLESCENT; ALLELE; ARTICLE; BEHAVIOR DISORDER; CHILD; CHILDHOOD AGGRESSION; CHILDHOOD DISEASE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD;

AGGRESSION; CANADA; CHILD; CHILD BEHAVIOR DISORDERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4;

EID: 84855940854     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.543431     Document Type: Article

References (92)

1. Achenbach TM, Rescorla LA. 2001. Manual for the ASEBA School-Age Forms and Profi les. Burlington, VT: University of Vermont, Research Centre for Children, Youth and Families.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. 2002. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159(8):1337-1346. (Pubitemid 34832715)
3. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. text revision. Washing-tonc, DC: American Psychiatric Association.
4. Archer J. 2004. Sex differences in aggression in real-world settings: a meta-analytic review. Rev Gen Psychol 8(4):291-322. (Pubitemid 40076723)
5. Arsenio WF. 2004. The stability of young children's physical aggression: relations with child care, gender, and aggression subtypes. Monogr Soc Res Child Dev 69(4):130-144.
6. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HHM. 1995. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65:1157-1165.
7. Bakermans-Kranenburg MJ, van Ijzendoorn MH. 2006. Gene-environment interaction of the dopamine D4 receptor (DRD4) and observed maternal insensitivity predicting externalizing behavior in preschoolers. Dev Psychobiol 48(5):406-409. (Pubitemid 44090286)
8. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. (Pubitemid 40202029)
9. Bartels M, Hudziak JJ, Van Den Ord EJ, Van Beijsterveldt CE, Rietveld MJ, Boomsma DI. 2003. Co-occurrence of aggressive behaviour and rule-breaking behaviour at age 12: multi-rater analysis. Behav Genet 33:607-621. (Pubitemid 37243305)
10. Bhana N, Foster RH, Olney R, Plosker GL. 2001. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111-161. (Pubitemid 32108327)
11. Brizer DA. 1988. Psychopharmacolgy and the management of violent patients. Psychiatr Clin North Am 11:551-568.
12. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. 2001. A randomized controlled trial of risperidone in the treat ment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62(4):239-248. (Pubitemid 32428762)
13. Buckley PF. 1999. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 60:52-60. (Pubitemid 29237176)
14. Campbell M, Small AM, Green WH, Jennings SJ, Perry R, Bennett WG, Anderson L. 1984. Behavioral effi cacy of haloperi-dol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41(7):650-656. (Pubitemid 14081378)
15. Caron C, Rutter M. 1991. Comorbidity in child psychopathology: concepts, issues, and research strategies. J Child Psychol Psychiatry 32:1063-1080.
16. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. 2002. Role of genotype in the cycle of violence in maltreated children. Science 297(5582):851-854. (Pubitemid 34839638)
17. Chalsani L, Kant R, Chengappa R. 2001. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood onset schizophrenia. Can J Psychiatry 46:965-968. (Pubitemid 34121561)
18. Chang FM, Kidd JR, Livak KJ, Pakstis AJ, Kidd KK. 1996. The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum Genet 98:91-101. (Pubitemid 26181289)
19. Chen CK, Chen SL, Mill J, Huang YS, Lin SK, Curran S, et al. 2003. The dopamine transporter gene is associated with atten tion defi cit hyperactivity disorder in a Taiwanese sample. Mol Psychiatry 8:393-396. (Pubitemid 36609663)
20. Chen TJH, Blum K, Mathews K, Fisher L, Schnautz N, Braverman ER, et al. 2005. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of " super normal controls " in psychiatric genetic research of complex behavioral disorders. Med Hypotheses 65:703-707. (Pubitemid 41021852)
21. Chengappa KN, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A, Schooler N. 2002. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res 53(1-2):1-6. (Pubitemid 33139769)
22. Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, et al. 2000. Comparison of the role of dopamine, serotonin, and noradrenalin genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. Clin Genet 57:178-196. (Pubitemid 30168746)
23. Daly G, Hawi Z, Fitzgerald M, Gill M. 1999. Mapping susceptibility loci in attention defi cit hyperactivity disorder: preferential transmission of parental alleles at DAT, DBH and DRD5 to affected children. Mol Psychiatry 4:192-196. (Pubitemid 29163984)
24. Deater-Deckard K, Plomin R. 1999. An adoption study of the etiology of teacher and parent reports of externalizing behaviour problems in middle childhood. Child Dev 70:144-154.
25. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV. 2003. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205-216. (Pubitemid 36204418)
26. Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, Gorwood P. 2004. The 3 ' region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res 67:75-85. (Pubitemid 38117094)
27. Eley TC, Lichtenstein P, Moffitt TE. 2003. A longitudinal behavioural genetic analysis of the etiology of aggressive and nona-gressive antisocial behaviour. Dev Psychopathol 15:383-402. (Pubitemid 351480051)
28. Faraone SV, Doyle AE, Mick E, Biederman J. 2001. Meta-analysis of the association between the 7-repeats of the dopamine D(4) receptor gene and attention defi cit hyperactiv-ity disorder. Am J Psychiatry 158:1052-1057. (Pubitemid 32623108)
29. Ferrari PF, Van Erp AM, Torantzky W, Miczek KA. 2003. Accum-bal dopamine and serotonin in anticipation of the next aggressive episode in rats. Eur J Neurosci 17:371-378. (Pubitemid 36459517)
30. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon ERN, Blumer JL. 2000. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516. (Pubitemid 30185547)
31. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. 2006. Effectiveness, safety, and pharma-cokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 45(7):792-800. (Pubitemid 43932905)
32. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. 2007. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol 17(1):1-9. (Pubitemid 46452077)
33. Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, et al. 2009. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychop-harmacol 19(4):431-439.
34. First MB, Spitzer RL, Gibbon M, Williams JBW. 1997. Structured Clinical Interview for DSM IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute.
35. Fresan A, Camarena B, Apiquian R, Aguilar A, Urraca N, Nicolini H. 2007. Association study of MAO-A and DRD4 genes in schizophrenic patients with aggressive behavior. Neuropsychobiology 55(3-4):171-175. (Pubitemid 47525237)
36. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacog-enomics J 1:152-156. (Pubitemid 33757602)
37. Garmendia L, S á nchez JR., Azpiroz A, Brain PF, Sim ó n VM. 1992. Clozapine: strong antiaggressive effects with minimal motor impairment. Physiol Behav 51:51-54.
38. Gauderman WJ, Morrison JM. 2006. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies [http://hydra.usc.edu/gxe].
39. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. 1997. Confi rma-tion of association between attention defi cit hyperactivity disorder and a dopamine transporter. Mol Psychiatry 2:311-313. (Pubitemid 27450313)
40. Giros B, El Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG. 1992. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383-390. (Pubitemid 23024654)
41. Gorman EB, Klorman R, Thatcher JE, Borgstedt AD. 2006. Effects of methylphenidate on subtypes of attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:808-816. (Pubitemid 43932907)
42. Greenwood TA, Kelsoe JR. 2003. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82:511-520. (Pubitemid 37239027)
43. Guo G, Roettger ME, Shih JC. 2007. Contributions of the DAT1 and DRD2 genes to serious and violent delinquency among adolescents and young adults. Hum Genet 121(1):125-136. (Pubitemid 46421149)
44. Ito H, Nara H, Inoue-Murayama M, Shimada MK, Koshimura A, Ueda Y, et al. 2004. Allele frequency distribution of the canine dopamine receptor D4 gene exon III and I in 23 breeds. J Vet Med Sci 66(7):815-820. (Pubitemid 41380263)
45. Jovanovic V, Guan HC, Van Tol HH. 1999. Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants. Pharmacogenetics 9:561-568.
46. Käll L, Storey JD, Noble WS. 2009. QVALITY: non-parametric estimation of q-values and posterior error probabilities. Bioin-formatics 25(7):964-966.
47. Kim JW, Park CS, Hwang JW, Shin MS, Hong KE, Cho SC, Kim BN. 2006. Clinical and genetic characteristics of Korean male alcoholics with and without attention defi cit hyperactivity disorder. Alcohol Alcohol 41(4):407-411.
48. Kim YR, Kim JH, Kim SJ, Lee D, Min SK. 2008. Catechol-O-methyltransferase Val158Met polymorphism in relation to aggressive schizophrenia in a Korean population. Eur Neuropsychopharmacol 18(11):820-825.
49. Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, Moffitt TE. 2006. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry 11(10): 903-913. (Pubitemid 44470213)
50. Lahiri DK, Nurnberger JI. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444.
51. LaHoste GJ, Swanson JM, Wiqal SB, Glabe C, Wiqal T, King N, Kennedy JL. 1996. Dopamine D4 receptor gene polymorphism is associated with attention defi cit hyperactivity disorder. Mol Psychiatry 1:121-124. (Pubitemid 126442401)
52. Lichter J, Barr C, Kennedy J, Van Tol H, Kidd K, Livak K. 1993. A hypervariable segment in the human dopamine receptor D 4 (DRD4) gene. Hum Mol Genet 2:767-773. (Pubitemid 23197523)
53. Lonergan E, Luxenberg J, Colford J. 2001. Haloperiodal for agitation in dementia (Cochrane Review). Cochrane Database Syst Rev 4:CD002852.
54. Maxwell E. 1992. The Family Interview for Genetic Studies: Manual. Clinical Neurogenetics Branch, Intramural Research Program. Washington, DC: National Institute of Mental Health [http://zork.wustl.edu/nimh/fi gs/fi gs-train.pdf].
55. Miczek KA, Fish EW, de Bold JF, de Almeida RMM. 2002. Social and neural determinants of Aggressive behavior: Pharmaco-therapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology 163:434-458.
56. Miles DR, Carey G. 1997. Genetics and environmental architecture of human aggression. J Pers Soc Psychol 72:207-217. (Pubitemid 127454508)
57. Miller GM, Madras BK. 2002. Polymorphisms in the 3 '-untranslated region of human and monkey dopamine transporter genes effect reporter gene expression. Mol Psychiatry 7:44-55. (Pubitemid 34087878)
58. Min KA, Palmatier MA, Kidd KK. 1999. Global variation of a 40-bp VNTR in the 3 '-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46:151-160. (Pubitemid 29320066)
59. Moffitt TE, Caspi A, Harrington H, Milne BJ, 2002, Males on the life-course-persistent and adolescence-limited antisocial pathways: Follow-upat age 26 years. Dev Psychopathol, 14, 1, 179-207. (Pubitemid 351690114)
60. Mungas D, Weiler P, Franzi C, Henry R. 1989. Assessment of disruptive behavior associated with dementia: the Disruptive Behavior Rating Scales. J Ger Psychiatry Neurol 2(4):196-202. (Pubitemid 20142162)
61. Neville MJ, Johnstone EC, Walton RT. 2004. Identifi cation and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23: 540-545. (Pubitemid 38720604)
62. Nottelman ED, Jensen PS. 1995. Comorbidity of disorders in children and adolescents: Developmental perspectives. In Ollendic, Prinz RJ, editors. Advances in clinical child psychology. Vol. 17. New York: Plenum. p 109-155.
63. Noble EP. 1998. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 16:33-45. (Pubitemid 28303920)
64. Paashius-Lew YR, Heddle JA. 1998. Spontaneous mutation during fetal development and post-natal growth. Mutagenesis 13(6):613-617. (Pubitemid 28523825)
65. Pohjalainen J, Rinne JO, Nagren K, Lehikoinen P, Anttile K, Syvalahti EKG, Hietala J. 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3:256-260. (Pubitemid 28266335)
66. Pritchard AL, Ratcliffe L, Sorour E, Haque S, Holder R, Bentham P, Lendon CL. 2009. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 24(9):1020-1025.
67. Purper-Ouakil D, Wohl M, Mouren MC, Verpillat P, Ades J, Gorwood P. 2005. Meta-analysis of family-based association studies between the dopamine transporter gene and attention defi cit hyperactivity disorder. Psychiatr Genet 15:53-59. (Pubitemid 40411571)
68. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. 2006. A randomized, double-blind, placebo-controlled study of risp-eridone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163(3): 402-410. (Pubitemid 44469381)
69. Rhee SH, Waldman ID. 2002. Genetic and environmental infl u-ences on antisocial behavior: a meta-analysis of twin and adoption studies. Psychol Bull 128(3):490-529.
70. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. 2002. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 63(3):241-244. (Pubitemid 34407084)
71. Rodriguiz RM, Chu R, Caron MG, Wetsel WC. 2004. Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res 148:185-198. (Pubitemid 37543667)
72. Sharp SI, McQuillin A, Gurling HM. 2009. Genetics of attention-defi cit hyperactivity disorder (ADHD). Neuropharmacology 57(7-8):590-600.
73. Sheese BE, Voelker PM, Rothbart MK, Posner MI. 2007. Parenting quality interacts with genetic variation in dopamine receptor D4 to infl uence temperament in early childhood. Dev Psychopathol 19(4):1039-1046. (Pubitemid 47578011)
74. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; Risperidone Conduct Study Group. 2002. Effects of risperi-done on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41(9):1026-1036. (Pubitemid 38338050)
75. Strous RD, Bark N, Parsia SS, Volavka J, Lachman HM. 1997. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res 69(2-3): 71-77. (Pubitemid 27147929)
76. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, et al. 2000. Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21-25. (Pubitemid 30026142)
77. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. 1998. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol 55(10):1335-1340. (Pubitemid 28465867)
78. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. 1997. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human straitum associated with the A1 allele. Pharma-cogenetics 7:479-484. (Pubitemid 27517576)
79. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. 2010. A common polymorphism in the Cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 35(6):1315-1324.
80. Todd RD, Jong YJ, Lobos EA, Reich W, Heath AC, Neuman RJ. 2001. No association of the dopamine transporter gene 3 ' VNTR polymorphism with ADHD subtypes in a population sample of twins. Am J Med Genet 105:745-748. (Pubitemid 33101475)
81. Van Beijsterveldt CE, Bartels M, Hudziak JJ, Boomsma DL. 2003. Cause of stability of aggression from early childhood to adolescence: a longitudinal analysis in Dutch twins. Behav Genet 33:591-605. (Pubitemid 37243304)
82. Van Bellinghen M, De Troch C. 2001. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11(1): 5-13. (Pubitemid 32295178)
83. Van Craenenbroeck K, Clark SD, Cox MJ, Oak JN, Liu F, Van Tol HH. 2005. Folding effi ciency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem 280(19):19350-19357. (Pubitemid 41379642)
84. Van den Oord EJ, Verhulst FC, Boomsma DI. 1996. A genetic study of maternal and paternal ratings of problem behaviors in 3-year-old twins. J Abnorm Psychol 105:349-357. (Pubitemid 26268704)
85. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin DA, Li X, Jabs EW, Uhl GR. 1992. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106. (Pubitemid 23053054)
86. Van den Berg SW, Dollé ME, Imholz S, van der A DL, van 't Slot R, Wijmenga C, et al. 2009. Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. Int J Obes (London) 33:1143-1152.
87. Vaughn MG, Delisi M, Beaver KM, Wright JP. 2009. DAT1 and 5HTT are associated with pathological criminal behavior in a nationally representative sample of youth. Criminal Justice and Beh. 36:1113-1124.
88. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, et al. 1998. Association and linkage of the dopamine transporter gene and attention-defi cit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 63:1767-1776. (Pubitemid 30415740)
89. Wechsler D. 1991. Manual for the Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, TX: The Psychological Corporation.
90. Wigginton JE, Abecasis GR. 2005. PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics 21:3445-3447. (Pubitemid 41222458)
91. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, et al. 2006. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 14:1-7.
92. Yodofsky SC, Silver JM, Schneider SE. 1987. Pharmacologic treatment of aggression. Psychiatr Ann 17:397.